How I Use Molecular Diagnostic Tests in Patients with MDS or Suspected MDS
David Steensma, MD, Dana-Farber Cancer Institute
Saturday, September 9, 2017 10:55 a.m.
Fairmont Chicago, Millennium Park, Chicago, IL
The availability of inexpensive next-generation DNA sequencing assays is changing hematology practice. Well-designed sequencing panels can provide confirmation of the presence of a clonal disorder in patients with unexplained cytopenias, and mutation analysis influences prognosis in those with an established diagnosis of myelodysplastic syndromes (MDS). Sequencing results may in some cases suggest an alternate or concomitant diagnosis or may make a patient eligible for a clinical trial of a targeted therapy. However, clonal hematopoiesis is common in older patients and this, as well as technical challenges, can make diagnosis difficult. Dr. Steensma will discuss appropriate uses of molecular testing in patients with unexplained cytopenias and with MDS, outline key unanswered questions, and review several illustrative cases.
About the Speaker
David Steensma, MD, is a Senior Physician at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. His clinical and research focus is myelodysplastic syndromes and marrow failure disorders. Dr. Steensma has led a number of multicenter trials of hypomethylating agents and hematopoietic growth factors in patients with myelodysplastic syndromes, other myeloid neoplasms, and marrow failure syndromes. He is currently the principal investigator of a study of the first-in-human spliceosome modulator for patients with MDS or AML and mRNA splicing mutations.
back to top